Alpha-galactosidase - Greenovation Biotech

Drug Profile

Alpha-galactosidase - Greenovation Biotech

Alternative Names: MOSS-AGAL; Moss-agalsidase; Moss-αGal

Latest Information Update: 09 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Greenovation Biotech
  • Class Carminatives; Enzymes; Recombinant proteins
  • Mechanism of Action Alpha-galactosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fabry's disease

Most Recent Events

  • 04 May 2016 Greenovation Biotech files a Clinical Trial Application with the Federal Institute for Drugs and Medical Devices in Germany for Fabry's disease
  • 01 May 2016 Phase-I clinical trials in Fabry's disease in Germany (IV)
  • 14 Sep 2015 The Federal Institute for Drugs and Medical Devices approves Clinical Trial Application for conducting a phase I trial of alpha-galactosidase in Fabry's disease in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top